Shanghai, China, 26 January 2022 — Shanghai Horizon Medical Technology Co., Ltd. (HorizonMedical™), recently received registration approval from the Zhejiang Medical Products Administration for its LOTUS™-SGN Single-use Sterile Single Lumen Ovum Aspiration Needle (LOTUS™-SGN) and LOTUS™ Double Lumen Ovum Aspiration Needle (LOTUS™ Double).
The oocyte retrieval needles are used for ultrasound-guided transvaginal oocyte retrieval, which, compared with transabdominal or laparoscopic oocyte retrieval, provides a better surgical field of view. With a higher retrieval rate and fewer complications, the use of these needles results in reduced surgical risk, faster recovery, and lower cost for patients.
The approved LOTUS™-SGN adopts a patented U-Tip® tip design in order to avoid tissue cutting during ovarian puncture and reduce the risk of bleeding in patients. LOTUS™-SGN has two models and a variety of tube sizes, the smaller of which is suitable for patients with fewer follicles after induction. The other approved product, LOTUS™ Double adopts inner and outer sleeve needle design. The inner needle cavity is used in drain oocytes, while the other needle cavity is used to flush the follicles, allowing continuous or intermittent suction and flushing operations.
As an innovative company specialized in providing medical technology solutions for assisted reproduction, HorizonMedical™ offers a range of products including oocyte retrieval needles, embryo transfer catheters, and insemination catheters. The approval of LOTUS™ II-SGN and LOTUS™ Double further enriches the product portfolio of HorizonMedical™. In the future, HorizonMedical™ will continue to invest in research and development as well as product innovation to provide inclusive and accessible total medical solutions in the field of assisted reproduction.
HorizonMedical™ is a subsidiary of MicroPort Scientific Corporation (MicroPort®, 00853.HK). Founded in November 2018, HorizonMedical™ is focused on medical solutions in the field of assisted reproductive technology (ART). Its business covers the R&D, manufacturing, marketing, and technical support of products at every step of the ART treatment process, including egg and sperm collection, fertilization, embryo culture, cryopreservation, and embryo transfer. HorizonMedical™ has established strong relationships and collaborations with many well-known IVF centers and universities across China, and it continues to engage with doctors and engineers to research and develop innovative products, to create a sound and open environment for innovation, and accelerate the commercialization and application of innovative medical products in the field of ART.